Skip to main content
. 2020 Nov;82(4):631–644. doi: 10.18999/nagjms.82.4.631

Table 1.

Patient characteristics and effectiveness of TMZ+Bev

Best overall
response
Progression-free
survival (months)
Overall
survival
(months)
Prognosis
Age Sex Primary organ Metastases Choi RECIST Choi RECIST
41 M meninges pancreas, lung SD SD 26.4 29.6 64.4+ alive
47 F meninges pelvis, bone SD SD 8.9 18.6 20.7+ alive
52 F meninges liver, lung SD SD 9.4 9.4 59.0 died
75 M pleura lymph nodes,
spleen, liver
PR PR 15.8 15.8 17.3+ alive